Phase III study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients.
Sign Up to like & getrecommendations! Published in 2021 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyab079
Abstract: BACKGROUND Palonosetron has demonstrated non-inferiority to ondansetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients in the United States and Europe. We conducted a single-arm registration study to evaluate the efficacy, safety and… read more here.
Keywords: chemotherapy; prevention chemotherapy; palonosetron; chemotherapy induced ... See more keywords
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002408
Abstract: Background: In this trial, we evaluated the safety and efficacy of olanzapine in children receiving highly emetogenic chemotherapy. Materials and Methods: In this study, patients aged 3 to 18 years were randomly assigned to either… read more here.
Keywords: olanzapine group; control; highly emetogenic; group ... See more keywords
Oral versus intravenous palonosetron in Chinese cancer patients receiving moderately emetogenic chemotherapy: A non-inferiority phase III trial.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of cancer care"
DOI: 10.1111/ecc.13245
Abstract: OBJECTIVE The 5-hydroxytryptamine-3 receptor antagonist palonosetron (PALO) is approved (United States/Europe) as an oral formulation for prevention of chemotherapy-induced nausea and vomiting in adult cancer patients undergoing moderately emetogenic chemotherapy (MEC) for the acute phase… read more here.
Keywords: chemotherapy; phase; non inferiority; oral versus ... See more keywords
Factors associated with neurokinin-1 receptor antagonist use among commercially insured cancer patients receiving highly emetogenic chemotherapy.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.5_suppl.24
Abstract: 24Background: Neurokinin-1 receptor antagonists (NK1RA) reduce chemotherapy-induced nausea/vomiting (CINV) among patients undergoing highly emetogenic chemotherapy (HEC). We evaluated factors associated with the use of NK1RA in patients treated with HEC. Methods: We performed a retrospective… read more here.
Keywords: chemotherapy; use; neurokinin receptor; factors associated ... See more keywords
Granisetron transdermal delivery system is effective in the control of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC) in China.
Sign Up to like & getrecommendations! Published in 2017 at "Chinese clinical oncology"
DOI: 10.21037/cco.2017.04.02
Abstract: Chemotherapy-induced nausea and vomiting (CINV) remains the major adverse effect of cancer treatment which impairs patients’ quality of life and affects their compliance with further treatment (1,2). read more here.
Keywords: chemotherapy; induced nausea; chemotherapy induced; granisetron transdermal ... See more keywords
Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy.
Sign Up to like & getrecommendations! Published in 2023 at "Future oncology"
DOI: 10.2217/fon-2022-0972
Abstract: Aim: Despite numerous available antiemetics, chemotherapy induced nausea and vomiting (CINV) still affects many patients, and CINV related hospitalizations and costs often result. Materials & methods: PrecisionQ analyzed its database to evaluate CINV related hospitalizations and costs following… read more here.
Keywords: hospitalization costs; moderately emetogenic; related hospitalization; emetogenic chemotherapy ... See more keywords
Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the National Comprehensive Cancer Network : JNCCN"
DOI: 10.6004/jnccn.2017.7043
Abstract: Purpose: Prevention of chemotherapy-induced nausea and vomiting is essential to preserve quality of life in patients with cancer receiving highly emetogenic chemotherapy (HEC). Recently, new drugs (eg, fosaprepitant, and the newer neurokinin-1 receptor antagonists [NK1RAs]… read more here.
Keywords: chemotherapy; use; patients receiving; receiving highly ... See more keywords